<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02162563</url>
  </required_header>
  <id_info>
    <org_study_id>CAIRO5</org_study_id>
    <secondary_id>2013-005435-24</secondary_id>
    <nct_id>NCT02162563</nct_id>
  </id_info>
  <brief_title>Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases</brief_title>
  <acronym>CAIRO5</acronym>
  <official_title>Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases CAIRO5 a Randomized Phase 3 Study of the Dutch Colorectal Cancer Group (DCCG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dutch Colorectal Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dutch Colorectal Cancer Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal cancer patients with initially unresectable liver-only metastases may be cured&#xD;
      after downsizing of metastases by neoadjuvant systemic therapy. However, the optimal&#xD;
      neoadjuvant induction regimen has not been defined, and no consensus exist on criteria for&#xD;
      resectability.&#xD;
&#xD;
      In this study colorectal cancer patients with initially unresectable liver-only metastases,&#xD;
      as prospectively confirmed by an expert panel according to predefined criteria, will be&#xD;
      tested for RAS and BRAF tumor mutation status and selected by location of primary tumor.&#xD;
      Patients with RAS or BRAF mutant and/or right sided tumors will be randomised between doublet&#xD;
      chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab (schedule 1), and triple chemotherapy&#xD;
      (FOLFOXIRI) plus bevacizumab (schedule 2). Patients with RAS AND BRAF wildtype AND left-sided&#xD;
      primary tumors will be randomized between doublet chemotherapy (FOLFOX or FOLFIRI) plus&#xD;
      either bevacizumab (schedule 1) or panitumumab (schedule 3). Patient imaging will be reviewed&#xD;
      for resectability by a central panel, consisting of at least one radiologist and three&#xD;
      surgeons every assessment. Central panel review will be performed prior to randomization as&#xD;
      well as during treatment, as described in the protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be stratified for resectability of liver metastases (potentially resectable&#xD;
      versus permanently unresectable), serum lactate dehydrogenase (LDH) (normal versus abnormal),&#xD;
      BRAF mutation status (wildtype versus mutated), type of neoadjuvant chemotherapy (FOLFIRI&#xD;
      versus FOLFOX) and hospital of registration.&#xD;
&#xD;
      Patients with RAS and BRAF wildtype and left-sided primary tumors will be randomised between&#xD;
      FOLFOX or FOLFIRI plus either bevacizumab or panitumumab. The choice between FOLFOX or&#xD;
      FOLFIRI is to the discretion of the local investigator, however, the treatment is restricted&#xD;
      to regimens that are specified in the protocol. Patients with RAS or BRAF mutated and/or&#xD;
      right-sided primary tumors will be randomized between FOLFOX/ FOLFIRI (investigator choice)&#xD;
      plus bevacizumab or 5FU, irinotecan, oxaliplatin (FOLFOXIRI) plus bevacizumab.&#xD;
&#xD;
      Patients will be evaluated every 8 weeks by CT scan for disease status. The assigned systemic&#xD;
      treatment should be continued for at least 6 months or earlier in case of resectability,&#xD;
      progression of disease, unacceptable toxicity, or patient refusal. If after 6 months the&#xD;
      panel concludes that the patient is still not resectable, it is highly unlikely that&#xD;
      resectability will be achieved at all. Therefore the chemotherapy regimen may be reconsidered&#xD;
      after 6 months of treatment. These patients should continue with the targeted drug in&#xD;
      combination with chemotherapy, but the chemotherapy may be altered into a less toxic schedule&#xD;
      such as fluoropyrimidine monotherapy. The targeted drug should be continued until progression&#xD;
      or unacceptable toxicity. In patients who will become resectable and undergo secondary&#xD;
      surgery of liver metastases, the total duration of preoperative and postoperative treatment&#xD;
      together should be 6 months, with the chemotherapy schedule being administered according to&#xD;
      the assigned treatment arm. However in these patients the targeted drug (bevacizumab or&#xD;
      panitumumab) should not be continued after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 years after last patient in study</time_frame>
    <description>Time from registration until progression or death whichever comes first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0/1 secondary resection rate</measure>
    <time_frame>2 years after last patient in study</time_frame>
    <description>R0/1 secondary resection rate in each of the 4 study arms upon neoadjuvant treatment with chemotherapy plus targeted therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival</measure>
    <time_frame>8 years after last patient in study</time_frame>
    <description>From date of randomisation to death or last known to be alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>2 years after last patient in study</time_frame>
    <description>Response according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (AE)</measure>
    <time_frame>2 years after last patient in study</time_frame>
    <description>Patients will be evaluated for Adverse Events at the start of each treatment cycle according to CTCAE version 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response rate (pCR)</measure>
    <time_frame>2 years after last patient in study</time_frame>
    <description>Pathological complete response rate (pCR) of the resected lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative morbidity</measure>
    <time_frame>After surgery during two months</time_frame>
    <description>Patients will be evaluated for surgical morbidity during 2 months. Postoperative morbidity will be scored according 'Clavien Dindo Grade'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of evaluation by the panel with outcome</measure>
    <time_frame>2 years after last patient in study</time_frame>
    <description>CT-scans will be reviewed for liver resectability by expert panel before randomisation and during neo-adjuvant treatment (every 8 weeks).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">564</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>Arm B: FOLFOXIRI &amp; bevacizumab (inclusion completed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with RAS or BRAF mutated and/or right-sided tumors will receive 5FU, irinotecan, oxaliplatin (FOLFOXIRI) and bevacizumab.&#xD;
Intervention: FOLFOXIRI with bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A: FOLFOX/FOLFIRI &amp; bevacizumab (inclusion completed)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with RAS or BRAF mutated and/or right-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.&#xD;
Intervention: FOLFOX/FOLFIRI with bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: FOLFOX/FOLFIRI &amp; panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus panitumumab.&#xD;
Intervention: FOLFOX/FOLFIRI with panitumumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: FOLFOX/ FOLFIRI &amp; bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.&#xD;
Intervention: FOLFOX/FOLFIRI with bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX/ FOLFIRI with bevacizumab</intervention_name>
    <description>FOLFIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks&#xD;
FOLFOX6 + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks</description>
    <arm_group_label>Arm A: FOLFOX/FOLFIRI &amp; bevacizumab (inclusion completed)</arm_group_label>
    <arm_group_label>Arm C: FOLFOX/ FOLFIRI &amp; bevacizumab</arm_group_label>
    <other_name>- bevacizumab</other_name>
    <other_name>- irinotecan</other_name>
    <other_name>- leucovorin</other_name>
    <other_name>- 5-fluorouracil</other_name>
    <other_name>- oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOXIRI with bevacizumab</intervention_name>
    <description>FOLFOXIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 165 mg/m2 i.v. in 60 minutes, followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours, every 2 weeks</description>
    <arm_group_label>Arm B: FOLFOXIRI &amp; bevacizumab (inclusion completed)</arm_group_label>
    <other_name>- bevacizumab</other_name>
    <other_name>- irinotecan</other_name>
    <other_name>- oxaliplatin</other_name>
    <other_name>- leucovorin</other_name>
    <other_name>- 5-fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX/ FOLFIRI with panitumumab</intervention_name>
    <description>FOLFIRI + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks&#xD;
FOLFOX6 + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, and bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks</description>
    <arm_group_label>Arm D: FOLFOX/FOLFIRI &amp; panitumumab</arm_group_label>
    <other_name>- panitumumab</other_name>
    <other_name>- irinotecan</other_name>
    <other_name>- leucovorin</other_name>
    <other_name>- 5-fluorouracil</other_name>
    <other_name>- oxaliplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological proof of colorectal cancer&#xD;
&#xD;
          -  Initially unresectable metastases confined to the liver according to CT scan, obtained&#xD;
             ≤3 weeks prior to registration. Unresectability should be confirmed by the liver&#xD;
             expertpanel. Patients with small (≤ 1 cm) extrahepatic lesions that are not clearly&#xD;
             suspicious of metastases are eligible&#xD;
&#xD;
          -  Known mutation status of RAS and BRAF&#xD;
&#xD;
          -  WHO performance status 0-1 (Karnofsky performance status ≥ 70)&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  No contraindications for liver surgery&#xD;
&#xD;
          -  In case of primary tumor in situ: tumor should be resectable&#xD;
&#xD;
          -  In case of resected primary tumor: adequate recovery from surgery&#xD;
&#xD;
          -  Adequate organ functions, as determined by normal bone marrow function (Hb ≥ 6.0&#xD;
             mmol/L, absolute neutrophil count ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L), renal&#xD;
             function (serum creatinine ≤ 1.5x ULN and creatinine clearance, Cockroft formula, ≥ 30&#xD;
             ml/min), liver function (serum bilirubin ≤ 2 x ULN, serum transaminases ≤ 5x ULN)&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Expected adequacy of follow-up&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Extrahepatic metastases, with the exception of small (≤ 1 cm) extrahepatic lesions&#xD;
             that are not clearly suspicious of metastases&#xD;
&#xD;
          -  Unresectable primary tumor&#xD;
&#xD;
          -  Serious comorbidity or any other condition preventing the safe administration of study&#xD;
             treatment (including both systemic treatment and surgery)&#xD;
&#xD;
          -  Major cardiovascular events (myocardial infarction, severe/unstable angina, congestive&#xD;
             heart failure, CVA) within 12 months before randomisation&#xD;
&#xD;
          -  Uncontrolled hypertension, or unsatisfactory blood pressure control with ≥3&#xD;
             antihypertensive drugs&#xD;
&#xD;
          -  Previous systemic treatment for metastatic disease; previous adjuvant treatment is&#xD;
             allowed if completed ≥ 6 months prior to randomisation&#xD;
&#xD;
          -  Previous surgery for metastatic disease&#xD;
&#xD;
          -  Previous intolerance of study drugs in the adjuvant setting&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Second primary malignancy within the past 5 years with the exception of adequately&#xD;
             treated in situ carcinoma of any organ or basal cell carcinoma of the skin, or second&#xD;
             primary colorectal cancer.&#xD;
&#xD;
          -  Any concomitant experimental treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C.J.A. Punt, Prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center, Utrecht NL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R.J. Swijnenburg, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Center, Amsterdam NL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>M.J.G. Bond, Drs.</last_name>
    <phone>+31 6 20 58 16 94</phone>
    <email>m.j.g.bond-2@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>A.S. Melis</last_name>
    <email>A.Melis@iknl.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitair ziekenhuis Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Peeters</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wilhelmina Ziekenhuis</name>
      <address>
        <city>Assen</city>
        <state>Drenthe</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Flevoziekenhuis</name>
      <address>
        <city>Almere</city>
        <state>Flevoland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D.W. Sommeijer, dr.</last_name>
      <email>d.w.sommeijer@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>D.W. Sommeijer, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Nij Smellinghe</name>
      <address>
        <city>Drachten</city>
        <state>Friesland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S. Hovenga, dr.</last_name>
      <email>s.hovenga@nijsmellinghe.nl</email>
    </contact>
    <investigator>
      <last_name>S. Hovenga, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden, loc. Zuid</name>
      <address>
        <city>Leeuwarden</city>
        <state>Friesland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.B. Polée, dr.</last_name>
      <email>m.polee@znb.nl</email>
    </contact>
    <investigator>
      <last_name>M.B. Polée, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis</name>
      <address>
        <city>Sneek</city>
        <state>Friesland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G.J. Veldhuis, dr.</last_name>
      <email>g.veldhuis@antonius-sneek.nl</email>
    </contact>
    <investigator>
      <last_name>G.J. Veldhuis, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuis</name>
      <address>
        <city>Apeldoorn</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.M. Smit, dr.</last_name>
      <email>j.m.smit@gelre.nl</email>
    </contact>
    <investigator>
      <last_name>J.M. Smit, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rijnstate ziekenhuis</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R Blaisse</last_name>
      <email>rblaisse@rijnstate.nl</email>
    </contact>
    <investigator>
      <last_name>R Blaisse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Sint Jansdal Ziekenhuis</name>
      <address>
        <city>Harderwijk</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Temizkan, dr.</last_name>
      <email>m.temizkan@stjansdal.nl</email>
    </contact>
    <investigator>
      <last_name>M. Temizkan, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud UMC</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H. de Wilt, prof.dr.</last_name>
      <email>hans.dewilt@radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>H. de Wilt, prof.dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Streekziekenhuis Koningin Beatrix</name>
      <address>
        <city>Winterswijk</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P.P. Schiphorst, dr.</last_name>
      <email>p.p.schiphorst@skbwinterswijk.nl</email>
    </contact>
    <investigator>
      <last_name>P.P. Schiphorst, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atrium Medical Center</name>
      <address>
        <city>Heerlen</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F. Warmerdam, dr.</last_name>
      <email>fwm01@atriummc.nl</email>
    </contact>
    <investigator>
      <last_name>F. Warmerdam, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC+</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R.L.H. Jansen, dr.</last_name>
      <email>rob.jansen@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>R.L.H. Jansen, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laurentius Ziekenhuis</name>
      <address>
        <city>Roermond</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.O. Boer, dr.</last_name>
      <email>m.denboer@lzr.nl</email>
    </contact>
    <investigator>
      <last_name>M.O. Boer, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orbis Medical Center</name>
      <address>
        <city>Sittard</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F.L.G. Erdkamp, dr.</last_name>
      <email>f.erdkamp@orbisconcern.nl</email>
    </contact>
    <investigator>
      <last_name>F.L.G. Erdkamp, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VieCuri Medisch Centrum</name>
      <address>
        <city>Venlo</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H. Vestjens, dr.</last_name>
      <email>hvestjens@viecuri.nl</email>
    </contact>
    <investigator>
      <last_name>H. Vestjens, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLVG, locatie Oost</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Gerhards</last_name>
      <email>m.f.gerhards@olvg.nl</email>
    </contact>
    <investigator>
      <last_name>M Gerhards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s Hertogenbosch</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H. Sinnige, dr.</last_name>
      <email>h.sinnige@jbz.nl</email>
    </contact>
    <investigator>
      <last_name>H. Sinnige, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bravis Ziekenhuis</name>
      <address>
        <city>Bergen op Zoom</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Troost, dr.</last_name>
      <email>m.troost@bravis.nl</email>
    </contact>
    <investigator>
      <last_name>M Troost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>O.J.L. Loosveld, dr</last_name>
      <email>o.loosveld@amphia.nl</email>
    </contact>
    <investigator>
      <last_name>O.J.L. Loosveld, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>St. Anna Ziekenhuis</name>
      <address>
        <city>Geldrop</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Elkerliek Ziekenhuis</name>
      <address>
        <city>Helmond</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Vincent, drs.</last_name>
      <email>j.vincent@elkerliek.nl</email>
    </contact>
    <investigator>
      <last_name>J. Vincent, drs.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bravis Ziekenhuis</name>
      <address>
        <city>Roosendaal</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H.J. Droogendijk, dr.</last_name>
      <email>hdroogendijk@fzr.nl</email>
    </contact>
    <investigator>
      <last_name>H.J. Droogendijk, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint Elisabeth Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J.M.G.H. Van Riel, dr.</last_name>
      <email>j.riel@elisabeth.nl</email>
    </contact>
    <investigator>
      <last_name>J.M.G..H. van Riel, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TweeSteden Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. Van Alphen</last_name>
      <email>rvalphen@tsz.nl</email>
    </contact>
    <investigator>
      <last_name>R. van Alphen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bernhoven</name>
      <address>
        <city>Uden</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.H. Vos, dr.</last_name>
      <email>a.vos@bernhoven.nl</email>
    </contact>
    <investigator>
      <last_name>A.H. Vos, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum, loc. Veldhoven</name>
      <address>
        <city>Veldhoven</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R.M.H. Roumen, dr.</last_name>
      <email>r.roumen@mmc.nl</email>
    </contact>
    <investigator>
      <last_name>R.M.H. Roumen, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.P. Hendriks, dr.</last_name>
      <email>m.p.hendriks@mca.nl</email>
    </contact>
    <investigator>
      <last_name>M.P. Hendriks, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC, location AMC</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D.W. Sommeijer, Dr.</last_name>
      <email>d.w.sommeijer@amsterdamumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>R.J. Swijnenburg, Dr.</last_name>
      <phone>+31 20 5665570</phone>
      <email>r.j.swijnenburg@amc.uva.nl</email>
    </contact_backup>
    <investigator>
      <last_name>D.W. Sommeijer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC, location VUMC</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H.M.W. Verheul, prof. dr.</last_name>
      <email>h.verheul@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>H.M.W. Verheul, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T.M. Ruers, prof. dr.</last_name>
      <email>t.ruers@nki.nl</email>
    </contact>
    <investigator>
      <last_name>T.M. Ruers, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BovenIJ Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S.E. Dohmen, dr.</last_name>
      <email>s.dohmen@bovenij.nl</email>
    </contact>
    <investigator>
      <last_name>S.E. Dohmen, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLVG, locatie Oost</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E.D. Kerver, Dr.</last_name>
      <email>e.d.kerver@olvg.nl</email>
    </contact>
    <investigator>
      <last_name>E.D. Kerver, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLVG, locatie West</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.C. Ogilvie, dr.</last_name>
      <email>a.ogilvie@slaz.nl</email>
    </contact>
    <investigator>
      <last_name>A.C. Ogilvie, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rode Kruis Ziekenhuis</name>
      <address>
        <city>Beverwijk</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Spaarne Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G. de Klerk, dr.</last_name>
      <email>g.de.klerk@kg.nl</email>
    </contact>
    <investigator>
      <last_name>G. de Klerk, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tergooi</name>
      <address>
        <city>Hilversum</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.M.T. van der Velde, dr.</last_name>
      <email>avandervelden@tergooi.nl</email>
    </contact>
    <investigator>
      <last_name>A.M.T. van der Velde, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spaarne ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B. de Valk, dr.</last_name>
      <email>bdevalk@spaarneziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>B. de Valk, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westfriesgasthuis</name>
      <address>
        <city>Hoorn</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Waterlandziekenhuis</name>
      <address>
        <city>Purmerend</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J.A.C Brakenhoff, dr.</last_name>
      <email>brakenhoff@wlz.nl</email>
    </contact>
    <investigator>
      <last_name>J.A.C. Brakenhoff, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zaans Medical Center</name>
      <address>
        <city>Zaandam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A. van Bochove, dr.</last_name>
      <email>bochove.a@zaansmc.nl</email>
    </contact>
    <investigator>
      <last_name>A. van Bochove, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <state>Overijssel</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.S.L. Liem, dr</last_name>
      <email>m.s.l.liem@dz.nl</email>
    </contact>
    <investigator>
      <last_name>M.S.L. Liem, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <state>Overijssel</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.C.J.C. Legdeur, dr.</last_name>
      <email>m.legdeur@mst.nl</email>
    </contact>
    <investigator>
      <last_name>M.C.J.C. Legdeur, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuisgroep Twente</name>
      <address>
        <city>Hengelo</city>
        <state>Overijssel</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R Hoekstra</last_name>
      <email>r.hoekstra@zgt.nl</email>
    </contact>
    <investigator>
      <last_name>R. Hoekstra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <state>Overijssel</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.W.B. de Groot, dr.</last_name>
      <email>j.w.b.de.groot@isala.nl</email>
    </contact>
    <investigator>
      <last_name>J.W.B. de Groot, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <state>Utrecht</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C.J. Rodenburg, dr.</last_name>
      <email>c.rodenburg@meandermc.nl</email>
    </contact>
    <investigator>
      <last_name>C.J. Rodenburg, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Los, dr.</last_name>
      <email>m.los@antoniusziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>M. Los, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Admiraal de Ruyter ziekenhuis</name>
      <address>
        <city>Goes</city>
        <state>Zeeland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H. Van Halteren</last_name>
      <email>h.vanhalteren@adrz.nl</email>
    </contact>
    <investigator>
      <last_name>H. Van Halteren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bethesda ziekenhuis</name>
      <address>
        <city>Hoogeveen</city>
        <state>Zuid Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf</name>
      <address>
        <city>Delft</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.M.E.M. Bos, dr.</last_name>
      <email>M.Bos@rdgg.nl</email>
    </contact>
    <investigator>
      <last_name>M.M.E.M. Bos, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hagaziekenhuis</name>
      <address>
        <city>Den Haag</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.E.A. Portielje, dr.</last_name>
      <email>j.portielje@hagaziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>J.E.A. Portielje, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Haaglanden, Westeinde</name>
      <address>
        <city>Den Haag</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H.H. Helgason, dr.</last_name>
      <email>h.helgason@mchaaglanden.nl</email>
    </contact>
    <investigator>
      <last_name>H.H. Helgason, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Trajkovic, Drs.</last_name>
      <email>m.vidakovic@asz.nl</email>
    </contact>
    <investigator>
      <last_name>M. Trajkovic, Drs.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groene Hart Ziekenhuis</name>
      <address>
        <city>Gouda</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H.W. Kapiteijn, dr.</last_name>
      <email>h.w.kapiteijn@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>H.W. Kapiteijn, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ikazia Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Maasstad Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B. Haberkorn, dr.</last_name>
      <email>haberkornb@maasstadziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>B. Haberkorn, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.P. Hamberg, dr.</last_name>
      <email>p.hamberg@franciscus.nl</email>
    </contact>
    <investigator>
      <last_name>A.P. Hamberg, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franciscus Vlietland</name>
      <address>
        <city>Schiedam</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.B. Ruit, dr.</last_name>
      <email>j.ruit@franciscus.nl</email>
    </contact>
    <investigator>
      <last_name>J.B. Ruit, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Koopman, dr.</last_name>
      <email>m.koopman-6@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>M. Koopman, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Treant zorggroep</name>
      <address>
        <city>Emmen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R.S. de Jong, dr.</last_name>
      <email>r.s.dejong@mzh.nl</email>
    </contact>
    <investigator>
      <last_name>R.S. de Jong, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G.A.P. Hospers, dr</last_name>
      <email>g.a.p.hospers@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>G.A.P. Hospers, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.dccg.nl</url>
    <description>Website Dutch Colorectal Cancer Group</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 5, 2014</study_first_submitted>
  <study_first_submitted_qc>June 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2014</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Anti-EGFR</keyword>
  <keyword>Liver metastases</keyword>
  <keyword>R0 R1 liver resection</keyword>
  <keyword>Resectability of liver</keyword>
  <keyword>Liver expert panel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data will be stored in the international ARCAD database which is available to other researchers.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>As of 2023</ipd_time_frame>
    <ipd_access_criteria>Member of ARCAD</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

